Elicio Therapeutics, Inc. financial data

Symbol
ELTX on Nasdaq
Location
451 D Street, 5 Th Floor, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 227 % +38%
Debt-to-equity -735 % -391%
Return On Equity 1.12K %
Return On Assets -176 % -11.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.3M shares +51.6%
Common Stock, Shares, Outstanding 16.3M shares +58.5%
Entity Public Float 33.2M USD -29.5%
Common Stock, Value, Issued 163K USD +58.3%
Weighted Average Number of Shares Outstanding, Basic 16.1M shares +42.3%
Weighted Average Number of Shares Outstanding, Diluted 16.1M shares +42.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 32.7M USD +12.1%
General and Administrative Expense 11.9M USD -1.82%
Costs and Expenses 44.6M USD +8.03%
Operating Income (Loss) -44.6M USD -8.03%
Nonoperating Income (Expense) -9.96M USD -474%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -54.6M USD -41.3%
Earnings Per Share, Basic -3 USD/shares -121%
Earnings Per Share, Diluted -3 USD/shares -121%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.1M USD +545%
Assets, Current 22.6M USD +238%
Property, Plant and Equipment, Net 377K USD -36.9%
Operating Lease, Right-of-Use Asset 5.25M USD -14.5%
Assets 29.5M USD +87.5%
Accounts Payable, Current 3.87M USD +266%
Employee-related Liabilities, Current 1.28M USD +15.3%
Accrued Liabilities, Current 5.11M USD -4.04%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 9.92M USD +30.8%
Operating Lease, Liability, Noncurrent 4.61M USD -17.1%
Liabilities 27.7M USD +59.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -70K USD +70.6%
Retained Earnings (Accumulated Deficit) -216M USD -33.9%
Stockholders' Equity Attributable to Parent 1.83M USD
Liabilities and Equity 29.5M USD +87.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.1M USD +16.5%
Net Cash Provided by (Used in) Financing Activities 10.3M USD -6.31%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 16.3M shares +58.4%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 240K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.8M USD +405%
Deferred Tax Assets, Valuation Allowance 100M USD +11.1%
Operating Lease, Liability 5.57M USD -13.3%
Depreciation 292K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -54.4M USD -40%
Lessee, Operating Lease, Liability, to be Paid 6.72M USD -16.6%
Property, Plant and Equipment, Gross 2.04M USD +2.26%
Operating Lease, Liability, Current 952K USD +11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.43M USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.38M USD +2.44%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.15M USD -29.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.47M USD +2.95%
Deferred Tax Assets, Operating Loss Carryforwards 64.6M USD +6.51%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.1M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.51M USD +3.07%
Operating Lease, Payments 334K USD -11.9%
Additional Paid in Capital 218M USD +36.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.01M USD +48.5%
Interest Expense 753K USD -89.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%